-
Company Insights
Business of the Formula E 2023-24 – Property Profile, Sponsorship and Media Landscape
The ‘Business of the Formula E’ report offers the following expert insights: A comprehensive overview of the Formula E league that is well regarded as one of the cleanest motorsport competitions taking place around the world. Breakdown of the main commercial deals around each of the 11 competing teams from a sponsorship perspective. Evaluation of leading players, team sponsorship, and team profiles. Sponsorship and media revenue generated for the Formula E 2023-2024 season. How is our ‘Business of the Formula...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Sarcomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etigilimab in Sarcomas Drug Details: Etigilimab (OMP-313M32) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etigilimab in Endometrial Cancer Drug Details: Etigilimab (OMP-313M32) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etigilimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Etigilimab (OMP-313M32)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Etigilimab in Solid Tumor Drug Details:Etigilimab (OMP-313M32) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navicixizumab in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Metastatic Colorectal Cancer Drug Details:Navicixizumab (OMP-305B83) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etigilimab in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etigilimab in Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Etigilimab in Uveal Melanoma Drug Details:Etigilimab (OMP-313M32) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navicixizumab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Gastric Cancer Drug Details:Navicixizumab (OMP-305B83) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navicixizumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Triple-Negative Breast Cancer (TNBC) Drug Details:Navicixizumab (OMP-305B83) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Navicixizumab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Navicixizumab (OMP-305B83)...